Pharming Group (NASDAQ:PHAR) Shares Gap Down – Here’s Why

Pharming Group (NASDAQ:PHAR) gapped down prior to trading on Wednesday . The stock had previously closed at $9.93, but opened at $9.43. Pharming Group shares last traded at $9.52, with a volume of 864 shares trading hands.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a research report on Tuesday, December 17th. Jefferies Financial Group began coverage on Pharming Group in a research report on Monday, December 9th. They issued a “buy” rating and a $14.00 price target for the company. Finally, Oppenheimer decreased their target price on Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, October 28th.

Pharming Group Trading Up 1.8 %

The stock has a market capitalization of $647.78 million, a PE ratio of -36.73 and a beta of -0.08. The firm has a 50-day moving average price of $8.82 and a 200-day moving average price of $8.37. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in shares of Pharming Group (NASDAQ:PHAR) by 16.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 47,997 shares of the company’s stock after acquiring an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. Institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.